Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients
Completed
Conditions studied: Venous Thromboembolism
In brief
Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.
Key facts
- Study ID
- NCT05226793
- Run by
- Methodist Health System
- People needed
- 400
- Starts
- 2021-11-17
- Expected to finish
- 2025-07-22
- Last updated by the study team
- 2025-07-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Effectiveness of intermediate-intensity vs standard prophylactic enoxaparin regimens on preventing DVT and/or PE in patients with COVID-19, measured using the following variables:
- Enoxaparin dose (appropriate for kidney function)
- Charlson comorbidity index (CCI) score
- Padua prediction score for risk of VTE
- IMPROVE [International Medical Prevention Registry on VTE] bleeding risk assessment score
- ICU status
- Number of thromboembolic events
- Length of stay
- Readmissions for DVT and/or PE
- In-hospital mortality with associated DVT or PE
You may not qualify if…
- Safety of intermediate-intensity vs standard prophylactic enoxaparin regimens in patients with COVID-19, measured using the following variables:
- Bleeding events
- Type of bleeding event
Where it is running
- Methodist Richardson Medical Center — Richardson, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.